PM
IDXG

Penbrook Management’s Interpace Biosciences, Inc. Common Stock IDXG Stock Holding History

Penbrook Management’s Portfolio IDXG Stock Details IDXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-84,400
Closed -$261K – 104
2020
Q3 		$261K Buy
84,400
+700
+0.8% +$3.17K 0.23% 84
2020
Q2 		$389K Buy
+83,700
New +$434K 0.38% 73

Other funds holding IDXG

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
AF
Allworth Financial Folsom, California $23.6B AUM 20.99% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $32.7B AUM 35.71% 1-Year Est. Return

Penbrook Management's IDXG Position: Q4 2020 in Review

Penbrook Management sold out of Interpace Biosciences, Inc. Common Stock (IDXG) in Q4 2020, closing a stake of 84,400 shares — an estimated $261K sold.

Penbrook Management first reported a position in IDXG in Q2 2020 and held it in 2 quarters. The position peaked at $389K in Q2 2020. 12 funds tracked by Wall St. Rank hold IDXG as of Q4 2020.

  • Penbrook Management reported no remaining Interpace Biosciences, Inc. Common Stock position as of Q4 2020 after selling out during the quarter.
  • Penbrook Management sold 84,400 Interpace Biosciences, Inc. Common Stock shares in Q4 2020, an estimated $261K.
  • Penbrook Management first reported a position in Interpace Biosciences, Inc. Common Stock in Q2 2020 and held it in 2 quarters.
  • Penbrook Management's Interpace Biosciences, Inc. Common Stock position peaked at $389K in Q2 2020.
  • 12 funds tracked by Wall St. Rank held Interpace Biosciences, Inc. Common Stock as of Q4 2020.

Based on Penbrook Management's 13F filing for Q4 2020, filed 27 Jan 2021.